Edition:
India

ARCA Biopharma Inc (ABIO.OQ)

ABIO.OQ on NASDAQ Stock Exchange Capital Market

7.42USD
25 Jun 2019
Change (% chg)

$0.75 (+11.24%)
Prev Close
$6.67
Open
$6.72
Day's High
$7.70
Day's Low
$6.72
Volume
109,036
Avg. Vol
155,248
52-wk High
$22.86
52-wk Low
$4.72

Latest Key Developments (Source: Significant Developments)

Arca Biopharma Reports Q1 Loss Per Share Of $1.86
Thursday, 9 May 2019 

May 8 (Reuters) - ARCA Biopharma Inc ::ARCA BIOPHARMA ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q1 LOSS PER SHARE $1.86.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $8.0 MILLION AS OF MARCH 31, 2019, COMPARED TO $6.6 MILLION AS OF DEC 31, 2018.ARCA BIOPHARMA-SEES CURRENT CASH, CASH EQUIVALENTS,MARKETABLE SECURITIES TO BE SUFFICIENT TO FUND OPERATIONS, AT PROJECTED COST STRUCTURE,THROUGH END OF Q3 2019.ARCA BIOPHARMA - WILL NEED TO RAISE MORE CAPITAL TO FUND FUTURE OPERATIONS,DEVELOP GENCARO/OTHER PRODUCT CANDIDATES,COMPLETE PARTNERSHIP/OTHER STRATEGIC TRANSACTIONS.  Full Article

Arca Biopharma Announces Fiscal Year 2018 Financial Results
Thursday, 28 Feb 2019 

Feb 27 (Reuters) - ARCA Biopharma Inc ::ARCA BIOPHARMA ANNOUNCES FISCAL YEAR 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.ARCA BIOPHARMA - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $6.6 MILLION AS OF DECEMBER 31, 2018, COMPARED TO $11.8 MILLION AS OF DECEMBER 31, 2017.ARCA BIOPHARMA - BELIEVES THAT CURRENT CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WILL BE SUFFICIENT TO FUND ITS OPERATIONS THROUGH END OF Q3.  Full Article

Arca Biopharma Q3 Loss Per Share $0.11
Thursday, 15 Nov 2018 

ARCA Biopharma Inc ::ARCA BIOPHARMA ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 LOSS PER SHARE $0.11.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALED $8.1 MILLION AT QUARTER-END.  Full Article

ARCA Biopharma Submits Special Protocol Assessment Request To FDA For Gencaro Phase 3 Atrial Fibrillation Clinical Trial
Tuesday, 18 Sep 2018 

Sept 18 (Reuters) - ARCA Biopharma Inc ::ARCA BIOPHARMA SUBMITS SPECIAL PROTOCOL ASSESSMENT REQUEST TO FDA FOR GENCARO PHASE 3 ATRIAL FIBRILLATION CLINICAL TRIAL.ARCA BIOPHARMA INC - SPA SUBMISSION IS NEXT STEP IN BEGINNING A PHASE 3 PROGRAM FOR GENCARO AFTER AN END-OF-PHASE 2 MEETING WITH FDA IN JUNE 2018.ARCA BIOPHARMA INC - PROTOCOL INCLUDED WITH SPA REQUEST INCORPORATES GUIDANCE ARCA RECEIVED FROM FDA REGARDING A PHASE 3 PROGRAM.  Full Article

Arca Biopharma Q2 Loss Per Share $0.15
Friday, 10 Aug 2018 

Aug 9 (Reuters) - ARCA Biopharma Inc ::ARCA BIOPHARMA ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.15.  Full Article

Genetic-AF Phase Presents 2B Clinical Trial Results At European Society Of Cardiology Heart Failure 2018 World Congress
Tuesday, 29 May 2018 

May 29 (Reuters) - ARCA Biopharma Inc ::GENETIC-AF PHASE 2B CLINICAL TRIAL RESULTS PRESENTED IN LATE BREAKING PRESENTATION AT EUROPEAN SOCIETY OF CARDIOLOGY HEART FAILURE 2018 WORLD CONGRESS.ARCA BIOPHARMA INC - IN OVERALL STUDY POPULATION, PHARMACOGENETIC GUIDED GENCARO(TM) DID NOT REDUCE AF/AFL/ACM RECURRENCE COMPARED TO TOPROL-XL.ARCA BIOPHARMA INC - IN U.S. PATIENTS, A TREND FOR POTENTIAL BENEFIT IN FAVOR OF GENCARO WAS OBSERVED FOR PRIMARY ENDPOINT OF ALL-CAUSE MORTALITY.ARCA BIOPHARMA - TREND FOR POTENTIAL BENEFIT IN FAVOR OF GENCARO OBSERVED IN A SUBSET OF PATIENTS FROM U.S., CANADA AND EUROPE.ARCA BIOPHARMA - SAFETY DATA INDICATED THAT GENCARO WAS WELL-TOLERATED IN AF-HFREF POPULATION INVESTIGATED WITH A SAFETY PROFILE SIMILAR TO TOPROL-XL.ARCA BIOPHARMA -PHASE 2B DATA SUPPORT POTENTIAL ADDITIONAL DEVELOPMENT OF GENCARO AS TREATMENT FOR ATRIAL FIBRILLATION IN HEART FAILURE PATIENTS.ARCA BIOPHARMA -BELIEVES TYPE OF POPULATION, IN WHICH AF IS BEING DRIVEN BY UNDERLYING HF PATHOPHYSIOLOGY, WOULD BE FOCUS OF ANY FUTURE GENCARO TRIALS.ARCA BIOPHARMA - END-OF-PHASE 2 MEETING SCHEDULED WITH U.S. FDA FOR LAST WEEK OF JUNE TO REVIEW GENETIC-AF DATA.  Full Article

ARCA Biopharma Anticipates Meeting With FDA In Q2
Monday, 26 Feb 2018 

Feb 26 (Reuters) - ARCA Biopharma Inc ::ARCA BIOPHARMA REPORTS TOPLINE PHASE 2B RESULTS FOR GENETIC-AF CLINICAL TRIAL.ARCA BIOPHARMA INC - ‍ANTICIPATES MEETING WITH U.S. FDA IN Q2 OF 2018 TO REVIEW PHASE 2 DATA AND PHASE 3 DEVELOPMENT PLAN​.ARCA BIOPHARMA INC - ‍GENCARO DEMONSTRATES COMPARABLE EFFICACY TO ACTIVE CONTROL AND TREND FOR POTENTIAL GENCARO SUPERIORITY IN US PATIENT COHORT​.ARCA BIOPHARMA INC - ‍SAFETY DATA INDICATED THAT GENCARO WAS GENERALLY SAFE AND WELL-TOLERATED IN AF/HEART FAILURE POPULATION​.ARCA BIOPHARMA INC - ‍THREE PATIENTS DIED IN LONG-TERM TREATMENT EXTENSION PERIOD AFTER RECEIVING GENCARO FOR MORE THAN A YEAR​.ARCA BIOPHARMA INC - ‍ENDED 2017 WITH CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALING $11.8 MILLION​.ARCA BIOPHARMA - ‍BELIEVES FUNDS, WITH NET PROCEEDS OF ABOUT $3.4 MILLION RAISED IN JAN WILL BE SUFFICIENT TO FUND OPERATIONS THROUGH END OF 2018​.  Full Article

Arca Biopharma announces issuance of European patent on cardiovascular disease treatment methods
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Arca Biopharma Inc :Arca Biopharma announces issuance of European patent for treating cardiovascular diseases and conditions with a new chemical entity utilizing genetic targeting.Arca Biopharma- believes current cash, cash equivalents,marketable securities will be sufficient to fund its operations through end of Q2 of 2018​.  Full Article

ARCA Biopharma announces third quarter financial results
Friday, 10 Nov 2017 

Nov 9 (Reuters) - Arca Biopharma Inc :ARCA Biopharma announces third quarter 2017 financial results and provides business update.Q3 loss per share $0.39.ARCA Biopharma Inc - anticipate reporting top-line data for Genetic-AF clinical trial​ late in Q1 of 2018.ARCA Biopharma Inc - ‍expects research and development expenses in 2017 to be higher than 2016​.  Full Article

Arca Biopharma Inc says‍ it entered into amendment no. 1 to its capital on demand sales agreement
Tuesday, 22 Aug 2017 

Aug 21 (Reuters) - Arca Biopharma Inc ::Arca Biopharma Inc says‍ on Aug 21, co entered into amendment no. 1 to its capital on demand sales agreement, dated as of January 11, 2017 .Arca Biopharma-‍amendment increased maximum offering value of shares of co's stock which co may issue, sell from time to time under sales agreement​.Amendment ‍increased maximum aggregate offering value of shares by approximately $2.9 million, from $7.3 million to $10.2 million ​.  Full Article